Abstract
The prevalence of vitamin D insufficiency and deficiency has increased markedly in recent decades to current epidemic levels 1 . In parallel there has been an increase in the incidence of a range of immune-mediated conditions ranging from cancer to autoimmune and respiratory diseases, including chronic obstructive pulmonary disease and asthma 2, 3 . There is also an association with increased respiratory infections, which are the most common cause of asthma exacerbations 3 . Together, this has resulted in considerable interest in the therapeutic potential of vitamin D to prevent and improve treatment of asthma and other respiratory diseases. To this end, data from clinical trials involving supplementation with active vitamin D, or more commonly a precursor, are starting to emerge. This review considers mechanisms by which vitamin D may act on the immune system to dampen inappropriate inflammatory responses in the airway whilst also promoting tolerance and anti-microbial defence mechanisms that collectively maintain respiratory health.
Asthma
Heterogeneity in asthma phenotypes (referred to as endotypes) has been described and these endotypes demonstrate differential responsiveness to treatment, underpinned by distinct pathogenic mechanisms [4] [5] [6] [7] . Asthma is classically a steroid-sensitive Th2-type immune pathology 8 and the symptoms of asthma are well-controlled by β2-adrenergic agonists and inhaled corticosteroids in the majority of patients. However, these long-term treatments do not 'cure' the disease, and the daily regimen of inhalers and avoidance of asthma triggers has a significant negative impact on many patients' quality of life. Furthermore, there are endotypes of asthma in which corticosteroid treatment is clinically ineffective (steroid insensitive/refractory/resistant asthma) 9 . These steroid-refractory patients suffer considerable morbidity, and are both expensive and challenging to manage clinically.
Vitamin D biology
Vitamin D is primarily synthesised by ultraviolet-B radiation from sunlight photolysing skin resident 7-dehydrocholesterol into vitamin D3, but it is also be ingested in small amounts through the diet (e.g. in oily fish or dietary supplements). Vitamin D then undergoes step-wise metabolism, first by the enzyme CYP27A1 in the liver into 25-hydroxyvitamin D3 (25(OH)D), the major form of vitamin D in the body, and then by the mitochondrial enzyme CYP27B1 to the active metabolite (1α,25-dihydroxyvitamin D3 (1,25(OH)2D3)) 10 . 35, 36 . Furthermore corticosteroids, the corner-stone of asthma treatment, affect vitamin D metabolism and in particular increase VDR and CYP24A1 expression [37] [38] [39] .
It is most likely that the association between asthma and vitamin D insufficiency is multi- to host defence through direct anti-microbial activity, as well as by modulating innate and adaptive immunity in addition to wound repair. Although the focus of studies regarding antimicrobial peptide actions has been in bacterial infections, they also appear to be important for anti-viral and anti-fungal immunity 46, 47 . The enhancement of anti-microbial peptide expression by vitamin D is accompanied by modulation of the production of pro-inflammatory cytokines which is hypothesised to lead to enhanced pathogen clearance without an excessive inflammatory response 48 . Furthermore, vitamin D stimulates autophagy and autophagosome activity which are important in the anti-microbial response 49 .
Effects on the adaptive immune system
The primary, but complex, role of vitamin D in dendritic cell (DC) function is modulation of antigen presenting cell function 50, 51 . IL-17A, and other Th17-associated cytokines, play a central role in defence against bacterial and fungal mucosal infections. However excessive levels of these cytokines, particularly IL-17A, is implicated in severe asthma and other immune-mediated diseases. Many patients with severe asthma have a neutrophilic endotype that is associated with increased IL-17A levels/production [62] [63] [64] [65] [66] [67] . In addition to triggering neutrophilia, IL-17A promotes airway hyperresponsiveness and remodelling, steroid-resistance, and synthesis of pro-inflammatory cytokines [66] [67] [68] [69] . Vitamin D has been shown to reduce IL-17A responses, both in mice and in humans with severe asthma 65, 70 .
Effects on regulatory T lymphocyte responses
Regulatory T cells (Tregs) are essential to prevent and control inappropriate and excessive, immune responses including those associated with allergy and asthma (reviewed in 71 ).
However, the frequency and action of Tregs in addition to levels of anti-inflammatory IL-10 are diminished in asthma patients 72, 73 . For example, bronchial lavage from severe therapyresistant paediatric asthmatics contains lower levels of IL-10 compared to non-asthmatic subjects, whilst the production of IL-10 by PBMCs/T cells from both paediatric and adult severe asthma patients is reduced 74, 75 .
Vitamin D enhances multiple facets of Treg actions 76 .
In addition to enhancing distinct Treg subsets, vitamin D also affects many other immune regulatory pathways, for example lymphocyte ATP metabolism and CD200 expression.
CD200 suppresses the pro-inflammatory activity of local innate immune cells and 1,25(OH)2D3 has been shown to increase expression of CD200 on human peripheral and nasal airway human T cells 84 . ATP is a proinflammatory molecule that can be broken down into immunosuppressive adenosine via the action of 5'-ectonucleotidases CD39 (ATP/ADP into AMP) and CD73 (AMP into adenosine) 85 . Both CD39 and CD73 have been proposed as Treg markers and CD39 expression at least is downregulated in severe asthmatics 65, 86 . We have shown that in vitro, 1,25(OH)2D3 upregulates CD39 expression and that this contributes to suppression of IL-17A 65 .
Effects on corticosteroid responses
Early studies from our laboratory investigated immunological actions of glucocorticoids that were relevant to clinical efficacy. We demonstrated that peripheral blood CD4+ T cells from steroid refractory patients were unable to increase secretion of anti-inflammatory IL-10 in vitro . A steroid-enhancing role for vitamin D in severe asthma is strongly supported by observational studies, particularly in paediatric cohorts 25, 26 . In addition to our T cell studies, Zhang et al. 88 have pioneered studies of the anti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes in both steroid refractory and sensitive asthma patients.
We recently reported that dexamethasone upregulates IL-17A from PBMC and CD4+ T cells in vitro, and demonstrated a positive association between inhaled corticosteroid dose (beclomethasone equivalent) and IL-17A synthesis in culture. These data suggest that corticosteroids may contribute to progression in severe asthma by heightening the Th17 responses. Notably, vitamin D strongly inhibited the corticosteroid induced IL-17A in culture 65 .
Effects of vitamin D on airway remodelling
Airway remodelling in asthma irreversibly reduces lung function, and in general is poorlycontrolled with current therapies 89 . Vitamin D has been shown to reduce airway smooth muscle (ASM) mass, subepithelial deposition and goblet cell hyperplasia 90, 91 ( Figure 1) .
Similarly, an inverse correlation exists between ASM mass and serum 25(OH)D in paediatric asthmatics 20 , whilst addition of vitamin D derivatives to cultures of human ASMs impairs proliferation of cells 92 . Furthermore, vitamin D has been shown to reduce production of extracellular matrix proteins from fibroblasts and reduce expression of enzymes implicated in airway remodelling, namely ADAM33 and MMP9 [93] [94] [95] [96] .
Vitamin D and Fetal Development
The majority of asthmatic patients develop the disease within the first decade of life, often following on from the development of food allergies and hayfever in the first years of life -the atopic march 97 . This strongly suggests that events in the fetal environment and first months of life have a major effect on whether individuals develop asthma. Lower maternal intake of vitamin D and maternal vitamin D deficiency have been found to be associated with increased risk of wheeze/asthma during childhood, both in individual studies and a meta-analysis [98] [99] [100] [101] [102] .
However some studies show no affect [102] [103] [104] [105] others even an adverse affect 106, 107 ; disparity in outcomes from clinical studies could be due to a variety of factors summarized in Figure 3 . . In addition to its actions on the developing immune system, vitamin D has an important role in fetal lung development 113, 114 .
Clinical Trials of Vitamin D Therapies -Early Evidence
Given Data from other large trials in asthma are awaited.
Conclusions and viewpoint
Evidence from clinical initiatives is starting to emerge, in both asthma and respiratory infections. However the data are likely to be complex and reflect the heterogeneity in trial 
